Showing results (81-90 of 345) with videos related to

Sort By:
Pageof 35
Clinical Endocrinology|January 1, 1991
The relationship between growth hormone (GH) messenger ribonucleic acid levels and hormone release from individual cells derived from human GH-secreting pituitary adenomasL J Hofland, B Velkeniers, P M van Koetsveld, et al.
Toxicologic Pathology|December 22, 2007
Mouse skin models for carcinogenic hazard identification: utilities and challengesDave Lynch, Jessica Svoboda, Sumanth Putta, et al.
BJS Open|March 25, 2020
Prospective methods for identifying perioperative risk-assessment methods for patient safety over 20 years: a systematic reviewA J Heideveld-Chevalking, H Calsbeek, J Hofland, et al.
Annals of Medicine|November 26, 1999
Somatostatin receptors in the thymusD Ferone, P M van Hagen, A Colao, et al.
Frontiers in Bioscience (Landmark Edition)|March 11, 2009
Somatostatin receptor expression in thymic tumorsDiego Ferone, Liliana Montella, Annarosaria De Chiara, et al.
Endocrinology|September 1, 1995
Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotideL J Hofland, P M van Koetsveld, M Waaijers, et al.
European Journal of Endocrinology|August 1, 1995
Octreotide, but not bromocriptine, increases circulating insulin-like growth factor binding protein 1 levels in acromegalyW W de Herder, P Uitterlinden, A J van der Lely, et al.
Current Cancer Drug Targets|April 27, 2013
Combined treatment with PPAR-γ agonists in pancreatic cancer: a glimmer of hope for cancer therapy?Alessandra Dicitore, Michele Caraglia, Annamaria Colao, et al.
The Journal of Clinical Endocrinology and Metabolism|March 1, 1989
Heterogeneity of growth hormone (GH) release by individual pituitary adenoma cells from acromegalic patients, as determined by the reverse hemolytic plaque assay: effects of SMS 201-995, GH-releasing hormone and thyrotropin-releasing hormoneL J Hofland, P M van Koetsveld, C C van Vroonhoven, et al.
Endocrinology|December 24, 2010
Reversal of endogenous dopamine receptor silencing in pituitary cells augments receptor-mediated apoptosisHaneen Al-Azzawi, Kiren Yacqub-Usman, Alan Richardson, et al.
Pageof 35